Vitalik Backs PopVax’s Open-Source COVID Vaccine Push

Vitalik Buterin praises PopVax’s AI-built open-source COVID vaccine PVX-001, funded by Balvi, as it heads toward Australian clinical trials.

The d/acc roadmap is shipping. That was Vitalik Buterin’s message on X after PopVax cleared a production milestone most thought impossible four years ago.

Buterin, posting on X via @VitalikButerin, called the development a real-world example of decentralized accelerationism in motion. Open-source vaccines, he wrote, let the whole world participate in manufacturing and in understanding medical properties. Balvi, his philanthropic fund, backed the project.

The Vaccine Nobody Saw Coming

PopVax founder Soham Sankaran started with under $50,000 and no biology background. That is not a typo.

Four years ago Sankaran launched @PopVaxIndia convinced that generative AI for design and RNA for delivery would produce vaccines that legacy methods had failed to build. As @sohamsankaran laid on firefly.social, the clinical batch of PVX-001, their broadly-protective COVID-19 vaccine candidate, has been manufactured at their RNA Foundry in Hyderabad.

Australia is next. Clinical trials expected within months.

The RNA platform is their own. Not borrowed. Not licensed. Built from scratch in India by a team that didn’t exist half a decade ago.

Sankaran’s v/acc Manifesto and What It Actually Says

PVX-001 reaching clinical batch stage is one thing. Sankaran also dropped a manifesto.

He published what he calls the v/acc plan on firefly.social, outlining how PopVax intends to save one million lives each year by accelerating vaccine development. The diseases in the pipeline are HCV, tuberculosis, Strep A, and malaria. Collectively, those four take 2.4 million lives every year. Sankaran said all four are headed for clinical trials by next year.

That is an aggressive timeline. Ambitious doesn’t cover it.

The open-source model is the mechanism. Manufacturers globally can study the formula, replicate it, modify it. No gates. Buterin’s framing on X was explicit: the whole world should be able to participate. His d/acc thesis applied here isn’t theoretical. It’s a batch of RNA in Hyderabad cleared for human trials.

Who Is Funding This

Sankaran publicly thanked Buterin’s Balvi fund on firefly.social. Also thanked: the Gates Foundation, Coeff Giving, and Ren Philanthropy.

Then came the equity investors. As Sankaran posted on firefly.social, Dustin Moskovitz and Cari Tuna’s Good Ventures entered as the first outside equity backers. Alongside them: Viswacolluru, Dhaval Shroff, Aaryaman Vir, and Rishi Desai, among others. The investment round brings outside capital into PopVax for the first time.

Balvi’s involvement fits a pattern. Buterin created the fund specifically to back unconventional public health bets. A non-biologist building an AI-designed RNA vaccine in Hyderabad fits that profile squarely.

What Buterin’s Endorsement Actually Signals

This isn’t the first time Buterin has crossed into public health territory.

His d/acc philosophy has appeared repeatedly in his writing over the past two years. It calls for using open, distributed technologies to speed human progress, not just financial systems. PopVax is the clearest expression of that idea outside crypto yet.

PVX-001 still has to clear clinical trials. Australia is the first test. The results will determine whether an AI-designed, open-source, RNA-based COVID vaccine built by a startup in India can actually compete with what major pharmaceutical firms have spent billions developing.

Sankaran’s four-year run from a personal $50,000 bet to a Hyderabad RNA Foundry to Australian trials now carries Buterin’s name alongside it. The d/acc roadmap, as Buterin put it, is shipping. Whether PVX-001 ships into millions of arms is the question clinical data will answer.

The post Vitalik Backs PopVax’s Open-Source COVID Vaccine Push appeared first on Live Bitcoin News.